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Introduction
The adenosine triphosphate (ATP)-binding cassette (ABC) transporter breast cancer resistance protein (ABC subfamily G member 2, humans: ABCG2, rodents: Abcg2) influences drug disposition as it recognizes diverse drugs and drug metabolites as its substrates (e.g. rosuvastatin, sulfasalazine, mitoxantrone, topotecan, prazosin, dantrolene, ciprofloxacin, erlotinib, gefitinib) (Lee et al., 2015; Mao and Unadkat, 2015) . ABCG2 is expressed in the canalicular (bile-facing) membrane of hepatocytes and in the brush border membrane of kidney proximal tubule cells, where it promotes hepatobiliary and urinary excretion of drugs or drug metabolites. ABCG2 also limits oral absorption of drugs in the small intestine and restricts brain distribution of drugs, often in concert with P-glycoprotein (ABC subfamily B member 1, humans: ABCB1, rodents: Abcb1a/b), in brain capillary endothelial cells forming the bloodbrain barrier. Alterations in ABCG2 transport activity due to genetic polymorphisms or drugdrug interactions (DDIs) may lead to changes in the disposition of ABCG2 substrates, which may affect drug safety and efficacy. So far, ABCG2-mediated DDIs have been mainly studied in the intestine (Kruijtzer et al., 2002; Allred et al., 2011; Kusuhara et al., 2012; Custodio et al., 2014) and considerably less information is available with respect to DDIs leading to changes in the hepatobiliary excretion of drugs. This is most likely related to the fact that intestinal DDIs can be assessed by studying drug plasma pharmacokinetics whereas hepatic ABCG2-mediated DDIs may only lead to changes in drug concentrations in the liver and intestine without pronounced changes in drug plasma pharmacokinetics. For a better understanding of tissue DDIs non-invasive positron emission tomography (PET) imaging with radiolabeled drugs has been proposed as a useful tool (Kusuhara, 2013; Langer, 2016) .
Apart from direct inhibition of ABCG2, certain drugs may interfere with regulatory pathways controlling transporter expression in tissue, which could also give rise to transporter-mediated DDIs. It has for instance been shown in vitro using different cell lines that the epidermal growth factor receptor (EGFR) regulates cellular ABCG2 expression levels via its downstream signaling pathways (i.e. phosphatidyl-inositol 3-kinase (PI3K)/Akt), mitogen-activated protein kinase (MAPK)) (Takada et al., 2005 Porcelli et al., 2014) (Fig. 1) . EGFR-targeting tyrosine kinase inhibitors (TKIs) (e.g. gefitinib, erlotinib, afatinib, osimertinib), which are frequently used in the clinic for cancer treatment, inhibit EGFR-signaling pathways and may therefore cause a reduction in tissue ABCG2 expression levels, which could affect disposition of concomitantly administered ABCG2-substrate drugs. However, in vivo data on EGFR-mediated regulation of tissue ABCG2 expression levels are scarce. A possible confounding factor in the study of the influence of EGFR inhibition on ABCG2-mediated drug disposition may be the fact that most TKIs also directly inhibit ABCG2 transport activity (Hegedüs et al., 2012; D'Cunha et al., 2016) . Recently, transgenic mouse models with cell type-specific hepatic deletion of EGFR have been described (Natarajan et al., 2007; Lanaya et al., 2014) . Such mouse models lend themselves to studying in vivo the regulation of ABCG2 by EGFR in a "non-pharmacological" approach. A previous PET study has shown that hepatobiliary excretion of [ 11 C]erlotinib is mediated in mice by Abcg2 (Traxl et al., 2015) .
In the present study, we used [ 11 C]erlotinib as a model Abcg2 substrate and compared its hepatic disposition, using PET and magnetic resonance (MR) imaging, in EGFR ∆hep mice, which specifically lack EGFR in hepatocytes, with EGFR fl/fl mice, which have normal EGFR expression in all tissues. We hypothesized that deletion of EGFR in hepatocytes will lead to reduced hepatobiliary excretion of [ 11 C]erlotinib due to a downregulation of hepatic Abcg2.
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Materials and Methods
Chemicals and drugs
Unless otherwise stated, all chemicals were obtained from Merck (Darmstadt, Germany) or Sigma-Aldrich (St. Louis, MO, USA). All chemicals were used without further purification and were of at least analytical grade.
Animals
Healthy male EGFR ∆hep (lacking EGFR in hepatocytes of the liver, but not in other tissues) and EGFR fl/fl (harboring a loxP-flanked EGFR allele, having normal EGFR expression in all tissues) littermate control mice with a C57BL/6 background were generated as described previously (Natarajan et al., 2007) and bred in the mouse facilities of the Medical University of Vienna Syncom BV, Groningen, The Netherlands) as described previously (Bahce et al., 2013) .
Specific activity at the time of injection was 74.8 ± 35.2 GBq/µmol (n = 11 batches) and radiochemical purity was >98%. For intravenous (i.v.) 
PET/MR imaging
EGFR fl/fl (n = 6) and EGFR ∆hep (n = 5) mice each underwent a MR scan followed by a dynamic PET scan after i.v. injection of [ 11 C]erlotinib. For imaging, animals were pre-anesthetized in an induction chamber using isoflurane (Abbott Laboratories, Maidenhead, UK), placed on a heated (37°C) animal bed and the lateral tail vein was cannulated. Body temperature and respiration rate were constantly monitored (SA Instruments, Stony Brook, NY, USA). Isoflurane anesthesia (1.5-2.5% in oxygen) and heating were maintained for the entire imaging period.
Anatomical whole-body MR imaging was performed on a 1 Tesla benchtop ICON™ scanner (Bruker, Ettlingen, Germany) using a modified T 1 -weighted gradient echo sequence (T 1 -fast low angle shot) with the following parameters: echo time = 5 ms; repetition time = 25 ms; flip angle = 25°; field of view = 76 x 28 x 24 mm; matrix = 253 x 93; 32 slices; slice thickness = 0.75 mm; scan time = 6.25 minutes. For PET imaging, the animal bed was transferred into the gantry of a microPET Focus™ 220 system (Siemens Medical Solutions, Knoxville, TN, USA) and a 10-minute transmission scan using a 57 Co point source was recorded. Subsequently, [ 11 C]erlotinib (46.9 ± 14.6 MBq, corresponding to 0.47 ± 0.54 µg (range: 0.07 µg -2.05 µg) of unlabeled erlotinib, n = 11 batches) was administered as an i.v. bolus over 1 minute via the lateral tail vein and a 90-minute dynamic PET scan was initiated at the start of radiotracer injection with an energy window of 250-750 keV and a timing window of 6 nanoseconds.
Postimaging procedures
At the end of the PET scan, a terminal blood sample was withdrawn from the retro-orbital sinus vein and the animals were sacrificed by cervical dislocation while still under deep anesthesia.
The liver was removed and radioactivity of blood aliquots was measured in a Wallac Wizard containing the respective lysis buffer (for total cell extracts: RIPA buffer containing 50 mM Tris, pH 8.0, 150 mM sodium chloride, 1% Triton X-100, 0.5% sodium deoxycholate and 0.1% SDS;
for membrane-enriched cell extracts: 50 mM HEPES, pH 7.3, 150 mM sodium chloride, 10% glycerol, 1% Triton X-100, 1 mM EDTA and 1.5 mM magnesium chloride). The tissue was lysed using a Precellys ® Evolution Homogenizer (Bertin Instruments, Montigny-le-Bretonneux, France). Cell extracts were snap-frozen in liquid nitrogen and stored at -80°C until further processing.
Western blotting
For Western blotting, frozen extracts were thawed and centrifuged at 12,000 rpm at 4°C for 10 minutes. The protein concentration of the cleared lysate was determined using the Pierce™ BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA). 15 µg of lysed protein was re-suspended in denaturing protein-loading buffer and left at room temperature for 10 minutes. Proteins were separated by SDS-PAGE and transferred to polyvinylidene difluoride (PVDF) membranes. To determine EGFR, Abcg2 and Abcb1a/b protein expression levels, the following monoclonal rabbit antibodies were used in 1:1000 dilutions: EGFR (EGF Receptor (D38B1) XP ® Rabbit mAb #4267), Abcg2 (ABCG2 (D5V2K) XP ® Rabbit mAb #42078) and Abcb1a/b (Anti-P Glycoprotein antibody [EPR10364-57] (ab170904)). α-Tubulin (Monoclonal Anti-α-Tubulin antibody produced in mouse) was used as loading control in a 1:500 dilution.
For analysis of protein expression levels in liver tissue, all obtained bands were quantified by densitometry using ImageJ software (NIH, Bethesda, MD, USA) and normalized to α-Tubulin.
PET data analysis
The dynamic PET data were sorted into 25 frames, which incrementally increased in time length from 5 seconds to 20 minutes. All PET images were reconstructed using Fourier rebinning of the three-dimensional sinograms followed by a two-dimensional filtered back- 10 injection decay correction and attenuation correction. By applying a calibration factor derived from imaging a cylindrical phantom with a known radioactivity concentration, PET units were converted into units of radioactivity. Using the medical image data examiner software AMIDE (Loening and Gambhir, 2003) , left ventricle of the heart (image-derived blood curve), liver, gall bladder, duodenum, intestine, left kidney and urinary bladder were manually outlined on coregistered PET/MR images and concentration-time curves expressed in units of percent of the injected dose per milliliter or per gram (%ID/mL or %ID/g) were derived. It was assumed that the sum of radioactivity in the gallbladder, the duodenum and the intestine represented radioactivity in the bile excreted from the liver. From the concentration-time curves, the area under the curve (AUC) from 0-90 minutes was calculated using Prism 7 software (GraphPad Software, La Jolla, CA, USA).
Integration plot analysis
To estimate the rate constants for transfer of radioactivity from blood into liver (k uptake,liver , mL/min/g liver), from blood into kidney (k uptake,kidney , mL/min/g kidney), from liver into bile (k bile , min -1 ) and from kidney into urine (k urine , min -1 ), a graphical analysis method (integration plot) was used as described previously (Shingaki et al., 2015; Traxl et al., 2015) . K uptake,liver and k uptake,kidney were measured from 0.3-3.5 minutes after radiotracer injection using the integration plot method and the following equation:
where C t,organ is the radioactivity concentration in liver or kidney at time t and C t,blood is the radioactivity concentration in the left ventricle of the heart at time t. AUC 0-t,blood represents the area under the concentration-time curve in the left ventricle of the heart from time 0 to time t.
K uptake,organ can be obtained by performing linear regression analysis of a plot of C t,organ /C t,blood
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where C t,organ is the radioactivity concentration in the intestine (including gall bladder and duodenum) or urinary bladder at time t. AUC 0-t,organ represents the area under the concentration-time curve in the liver or kidney from time 0 to time t. K fluid (k bile or k urine ) can be obtained by performing linear regression analysis of a plot of C t,organ versus AUC 0-t,organ and calculating the slope of the regression line. V E is the y-intercept of the integration plot.
Statistical analysis
All values are given as mean ± standard deviation (SD). Statistical differences between groups were analyzed by two-tailed unpaired t-tests using Prism 7 software. To assess correlations, the Pearson correlation coefficient (r) was calculated. The level of statistical significance was set to a P value of less than 0.05.
This article has not been copyedited and formatted. The final version may differ from this version. Fig. 2 , indicating lower radioactivity content in the duodenum and intestine and higher radioactivity content in the urinary bladder of EGFR ∆hep mice as compared to EGFR fl/fl mice. In Fig. 3 866 ± 86 %ID/g*min).
To quantitatively evaluate hepatic disposition of [ 11 C]erlotinib, we employed a graphical analysis approach (integration plot analysis) using an image-derived blood curve to estimate the rate constants for transfer of radioactivity from blood into liver (k uptake,liver ) and from liver via bile into duodenum and intestine (k bile ). Radioactivity concentrations measured in the left ventricle of the heart in the last PET frame (70-90 minutes after radiotracer injection) showed a good correlation (r = 0.735, P < 0.05) with radioactivity concentrations measured with a gamma-counter in the venous blood sample collected at the end of the PET scan (data not shown). In Fig. 5 , integration plots and k uptake,liver and k bile values are shown for both mouse models. K uptake,liver was not significantly different, whereas K bile was significantly, by 3.0-fold, decreased in EGFR ∆hep compared to EGFR fl/fl mice (Table 1) .
We also studied distribution of [ 11 C]erlotinib to the kidney and urinary bladder and estimated the rate constants for transfer of radioactivity from blood into kidney (k uptake,kidney ) and from the two mouse models, whereas k urine was significantly, by 2.2-fold, higher in EGFR ∆hep mice.
EGFR, Abcb1a/b and Abcg2 protein expression levels in liver tissue
Western blot analysis of liver tissue collected at the end of PET imaging confirmed almost complete absence of EGFR protein expression levels in total cell extracts of EGFR ∆hep mice as compared to EGFR fl/fl mice (on average 16.2-fold reduction, P < 0.05) (Fig. 7A,B) . The residual, low EGFR signal in EGFR ∆hep mice most likely derives from non-parenchymal cells, in which EGFR was not deleted. In EGFR ∆hep mice, Abcg2 protein expression levels were significantly lower in total (on average 2.9-fold) as well as in membrane-enriched (on average 2.5-fold) cell extracts compared to EGFR fl/fl mice (Fig. 7A,D) , suggesting that the absence of EGFR does not affect the localization of the Abcg2 protein. In contrast, Abcb1a/b protein expression levels in the liver of EGFR ∆hep mice were significantly increased in total cell extracts (on average 3.1-fold), with a similar tendency in membrane-enriched cell extracts (on average 2.3-fold) (Fig. 
7A,C).
This article has not been copyedited and formatted. The final version may differ from this version. (Natarajan et al., 2007) . As there is evidence for sex specific differences in EGFR pathways in the liver of mice (Wang et al., 2016) and as the assessment of these sex differences was not the subject of the present study, we focused on male mice in our experiments. Several previous studies have provided evidence for a regulatory link between EGFR signaling and ABCG2 expression ( (Takada et al., 2005) . These regulatory pathways may either be exploited, for instance in order to overcome transporter-mediated chemoresistance of cancer cells, or they could also lead to unwanted DDIs, when a drug which interferes with EGFR signaling is combined with another drug which is transported by ABCG2. Most studies examining regulation of ABC transporters have employed cellular systems and few in vivo data are available to assess whether modulation of regulatory pathways translates into alterations of transporter-mediated disposition of probe substrates (Slosky et al., 2013; Wang et al., 2014) . Recent work has shown that PET with radiolabeled transporter substrates is a powerful tool to non-invasively measure the activities of different ABC and solute carrier (SLC) transporters in the living organism (Kusuhara, 2013; Langer, 2016) .
This article has not been copyedited and formatted. The final version may differ from this version. Erlotinib is a first-generation EGFR-targeting TKI, which is approved for the treatment of nonsmall cell lung and pancreatic cancer. Erlotinib has also been suggested as potential treatment for hepatocellular carcinoma (HCC), although a recent phase 3 study was unable to demonstrate survival improvement with erlotinib in advanced-stage HCC (Zhu et al., 2015) .
Erlotinib is predominantly excreted via the hepatobiliary route; in humans 83% of an i.v. dose was excreted in feces and only 8% in urine (Ling et al., 2006) . Erlotinib is a substrate of ABCG2
and ABCB1 (Kodaira et al., 2010) , which was shown to inhibit these transporters at higher concentrations (Shi et al., 2007) . Moreover, there is evidence that erlotinib downregulates cellular ABCG2 expression levels via EGFR inhibition (Porcelli et al., 2014) . We recently demonstrated that k bile of [ 11 C]erlotinib was 1.3-, 2.3-and 2.8-fold reduced in Abcb1a/b (-/-) ,
Abcg2 (-/-) and Abcb1a/b (-/-) Abcg2 (-/-) mice, respectively, relative to wild-type mice (Traxl et al., 2015) . Moreover, we found that the majority of radioactivity in plasma, liver and bile was composed of unmetabolized [ 11 C]erlotinib after i.v. injection of the radiotracer into wild-type mice, whereas only radiolabeled metabolites were detected in urine. These data provided evidence that hepatobiliary excretion of [ 11 C]erlotinib is mediated in mice by Abcg2 and to a lesser extent by Abcb1a/b, suggesting that [ 11 C]erlotinib may be used as a PET probe substrate to measure Abcg2 transport activity in the liver. In the present study we used [ 11 C]erlotinib to investigate if deletion of EGFR in hepatocytes leads to changes in hepatic Abcg2 transport activity. To obtain quantitative pharmacokinetic parameters of hepatic disposition of [ 11 C]erlotinib we estimated the transfer rate constants of radioactivity from blood into liver (k uptake,liver ) and from liver into bile (k bile ) using integration plot analysis (Shingaki et al., 2015; Traxl et al., 2015) (Fig. 5) . K bile is a parameter which has been used in other studies to assess canalicular ABC transport activities, such as that of Abcg2, in the liver of mice (Takashima et al., 2013) . 0.734 ± 0.106 mL/min/g tissue) indicating good reproducibility of our analytical method (Traxl et al., 2015) . There is evidence that hepatic uptake of [ 11 C]erlotinib is transporter-mediated as reflected by a decrease in k uptake,liver in wild-type mice co-injected with a therapeutic dose of unlabeled erlotinib as compared to mice which only received a PET microdose of [ 11 C]erlotinib (Traxl et al., 2015) . However, as opposed to certain low permeability drugs, for which hepatic disposition is to a large extent transporter-mediated (e.g. statins), erlotinib is a highly lipophilic compound which can be expected to also penetrate cellular membranes by passive diffusion.
K bile was 3.0-fold lower in EGFR ∆hep mice (Fig. 5D) , suggesting a decrease in biliary excretion of [ 11 C]erlotinib. The decrease in total as well as in membrane-bound hepatic Abcg2 expression levels in EGFR ∆hep mice as revealed by Western blot analysis (Fig. 7D ) suggested transcriptional regulation of Abcg2 protein levels by EGFR rather than an alteration in the membrane localization of Abcg2. Interestingly, there was an increase in hepatic Abcb1a/b expression levels (Fig. 7C ). This is in line with another study which assessed changes in transporter expression levels in human conditionally immortalized proximal tubule epithelial cells following treatment with the EGFR recombinant antibody cetuximab and found significant decreases in ABCG2 mRNA and increases in ABCB1 mRNA (Caetano-Pinto et al., 2017) . Our data thus support the premise that hepatobiliary excretion of [ 11 C]erlotinib is to a larger extent dependent on Abcg2 than on Abcb1a/b, as k bile was decreased in EGFR ∆hep mice despite an apparent upregulation of canalicular Abcb1a/b. Our data also provide evidence that [ 11 C]erlotinib PET is a sensitive tool to measure changes in Abcg2 transport activity in the liver.
Interestingly, despite the decrease in radioactivity excreted into bile, liver profiles were parallel ( Fig. 3B ) and liver-to-blood AUC ratios were not significantly different between both mouse models with a tendency for lower values in EGFR ∆hep mice (Fig. 4D) . On the other hand, blood AUC values were significantly higher in EGFR ∆hep mice (Fig. 4A ). This could be related to an increase in the transfer of speculative as the rate constant for transfer of radioactivity from liver into blood could not be determined with the presently employed analysis approach.
As erlotinib partly undergoes urinary excretion (Ling et al., 2006) we also measured distribution of [ 11 C]erlotinib to the kidneys and urinary bladder (Fig. 6) . In a previous study we found that urinary excretion of radioactivity following i.v. injection of [ 11 C]erlotinib was very low in wildtype mice and markedly increased in Abcg2 (-/-) and Abcb1a/b (-/-) Abcg2 (-/-) mice (Traxl et al., 2015) . This suggested a shift from hepatobiliary to renal excretion (which was apparently not mediated by renal Abcg2 and Abcb1a/b), when hepatobiliary excretion was impaired due to knockout of Abcg2. A similar phenomenon was observed in the present study, in which k urine was 2.2-fold higher in EGFR ∆hep as compared to EGFR fl/fl mice (Fig. 6D ).
Our in vivo data confirm previous in vitro data that EGFR signaling can regulate ABCG2 expression levels (Mogi et al., 2003; Takada et al., 2005; Meyer zu Schwabedissen et al., 2006; Pick and Wiese, 2012; Porcelli et al., 2014) . We provide, to our knowledge, the first evidence that EGFR deletion in hepatocytes translates in vivo into a decrease in Abcg2 transport activity leading to changes in disposition of an Abcg2 probe substrate. Our findings may have clinical relevance as they raise the possibility that treatment with EGFR inhibitors, such as TKIs or antibodies, may alter hepatic ABCG2 transport activity and thereby lead to changes in hepatobiliary clearance of concomitantly administered ABCG2 substrate drugs.
This may potentially lead to hepatotoxicity of drugs but could also prove beneficial in the treatment of liver tumors by prolonging liver residence times of anticancer drugs, if their biliary excretion is dependent on ABCG2 transport activity. It should be noted that our study was conducted with a microdose of erlotinib (~ 120-fold lower than a human oral therapeutic dose of 2 mg/kg). As erlotinib itself is a potent inhibitor of ABCG2 (half-maximum inhibitory concentration, IC 50: 0.13 µM) (Noguchi et al., 2009 ), ABCG2 transport activity may be saturated in the liver at therapeutic erlotinib doses, which may result in less pronounced effects of EGFR deletion on disposition of a therapeutic erlotinib dose. Transgenic mouse models with cell typespecific deletion of regulatory pathways or transporters may serve as valuable tools to assess the impact of transporters on drug disposition. (Mogi et al., 2003; Takada et al., 2005; Pick and Wiese, 2012; Porcelli et al., 2014) . section for the definition of variables used in the integration plots. K uptake,liver and k bile correspond to the slopes of the linear regression lines. ns, not significant, ***P < 0.001, two-tailed unpaired t-test. tissue collected after the PET scan from EGFR fl/fl mice (n = 3) and EGFR ∆hep mice (n = 3) using membrane-enriched and total cell extracts. Bands were quantified by densitometry using ImageJ software and protein expression levels were normalized to α-Tubulin, which was used as loading control (B-D). ns, not significant, *P < 0.05, **P < 0.01, two-tailed unpaired t-test.
